GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Return-on-Tangible-Equity

Bio-Rad Laboratories (Bio-Rad Laboratories) Return-on-Tangible-Equity

: 17.82% (As of Dec. 2023)
View and export this data going back to 1980. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bio-Rad Laboratories's annualized net income for the quarter that ended in Dec. 2023 was $1,399 Mil. Bio-Rad Laboratories's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $7,851 Mil. Therefore, Bio-Rad Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 17.82%.

The historical rank and industry rank for Bio-Rad Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

BIO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -33.04   Med: 6.54   Max: 51.77
Current: -7.71

During the past 13 years, Bio-Rad Laboratories's highest Return-on-Tangible-Equity was 51.77%. The lowest was -33.04%. And the median was 6.54%.

BIO's Return-on-Tangible-Equity is ranked worse than
58.54% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs BIO: -7.71

Bio-Rad Laboratories Return-on-Tangible-Equity Historical Data

The historical data trend for Bio-Rad Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.03 51.77 37.86 -33.04 -7.55

Bio-Rad Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.88 3.08 -55.56 5.52 17.82

Competitive Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Return-on-Tangible-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Return-on-Tangible-Equity falls into.



Bio-Rad Laboratories Return-on-Tangible-Equity Calculation

Bio-Rad Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-637.324/( (8876.652+8007.033 )/ 2 )
=-637.324/8441.8425
=-7.55 %

Bio-Rad Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=1398.832/( (7694.998+8007.033)/ 2 )
=1398.832/7851.0155
=17.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Bio-Rad Laboratories  (NYSE:BIO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Bio-Rad Laboratories Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Executives
Tania Devilliers officer: INT PRIN ACCTG OFC C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen officer: EVP, Global Human Resources 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May officer: EVP, President, LSG C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam officer: SVP, Chief Accounting Officer C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst officer: EVP, General Counsel & Sec 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright officer: Executive Vice President C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley officer: EVP, GBL Commercial Operations 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz 10 percent owner 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz director, 10 percent owner
Norman D Schwartz director, 10 percent owner, officer: Chairman, President, and CEO 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547

Bio-Rad Laboratories (Bio-Rad Laboratories) Headlines